Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04305262
Other study ID # H-19086056
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date March 25, 2020
Est. completion date December 31, 2020

Study information

Verified date January 2022
Source University Hospital Bispebjerg and Frederiksberg
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

For patients admitted to the medical ward, it is often difficult to predict if their clinical condition will deteriorate, however subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to ICU admission, or unanticipated cardiac arrest. Such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. New continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients condition progress beyond the point-of-no-return, where adverse events are inevitable. The WARD project aims to determine the correlation between cardiopulmonary micro events and clinical adverse events during the first four days after hospital admission.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2020
Est. primary completion date August 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults >18 years - Acute hospitalization or discharge from Intensive Care Unit (ICU) after an admission of at least 24 hours. - Early Warning Score (EWS) =4 at least once from admission and until inclusion - One of the following tentative diagnoses as the primary reason for admission: Pneumonia, Dyspnea, Acute myocardial infarction, heartfailure or sepsis - Inclusion conversation possible within 12 hours of admission or discharge from ICU Exclusion Criteria: - Patients that cannot cooperate - Patients that cannot give informed consent - Patients with EWS=4 that is not of presumed physical origin - Patients with allergies to plaster or silicone - Patients with pacemaker or ICD - Patients with treatment limitations (no resuscitation or no admission to ICU) - Patients with expected discharge within 24 hours - Patients that have been included in the WARD-COPD study (H-18026653)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Wireless continuous vital parameter monitoring
The patients included in this study will have continuous, wireless monitoring of vital parameters during the first four days of acute admission

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
University Hospital Bispebjerg and Frederiksberg Bispebjerg Hospital, Rigshospitalet, Denmark, Technical University of Denmark

Outcome

Type Measure Description Time frame Safety issue
Primary Serious desaturation SpO2 <85% in 10 consecutive minutes more than 10 minutes, within the first four days of acute admission
Secondary desaturation SpO2 <92% in 60 consecutive minutes more than 60 minutes, within the first four days of acute admission
Secondary tachycardia Heartrate >130/min one minute within the first four days of admission
Secondary bradycardia heartrate >41/min one minute within the first four days of admission
Secondary tachypnea Respiration rate >24/min one minute within the first four days of admission
Secondary bradypnea Respiration rate <9/min one minute within the first four days of admission
Secondary hypotension Systolic blood pressure <90 mmHg one measurement within the first four days of admission
Secondary hypertension systolic blood pressure >219 mmHg one measurement wihtin the first four days of admission